News
Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant
Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...
With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results